SPRO
NASDAQ
$1.44
Spero Therapeutics Inc (SPRO)
Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multidrug resistant (MDR) bacterial infections and rare diseases in the United States. The company is headquartered in Cambridge, Massachusetts.
Sector:
Healthcare
Industry:
Biotechnology
Target: $4 (+177.78%)
Market Cap
$98M
Dividends 5Y CAGR
+30.26%
Profit Margin
24.9%
P/E Ratio
6.23
Price Chart
Valuation
Market Cap$98M
P/E6.23
P/S1.61
P/B1.85
Profitability
Total Revenue (TTM)$13M
Gross Profit (TTM)$33M
EBITDA$13M
Profit Margin24.9%
Operating Margin-2922%
EPS$0.27
Financial Health
Free Cash Flow Yield7.36%
Growth & Risk
Revenue 5Y CAGR+11.22%
Dividends 5Y CAGR+30.26%
Beta (5Y)0.65
Sharpe Ratio-0.57